Wegovy vs Zepbound for Medicare patients.
Two of the most-prescribed GLP-1 medications for chronic weight management. Both work. Both are now reachable for eligible Medicare beneficiaries through the new federal CMS Bridge Program launching July 1, 2026.
Here’s how Wegovy® and Zepbound® actually differ, so you can be prepared when you meet with your provider.
For Medicare patients, the practical differences come down to mechanism, side-effect profile, and what your clinician determines is safest for your body. Under the Bridge Program, both medications cost $50/month if you qualify — so cost is not the deciding factor.
The facts, compared.
| Attribute | Wegovy® | Zepbound® |
|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly |
| Active ingredient | Semaglutide | Tirzepatide |
| How it works | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Delivery | Weekly self-injection | Weekly self-injection |
| FDA-approved for chronic weight management | Yes (2021) | Yes (2023) |
| Average weight loss in trials* | ~15% of body weight at 68 weeks | ~18–22% of body weight at 72 weeks |
| Cost under the Medicare Bridge Program** | $50 / month flat | $50 / month flat |
*Trial averages from manufacturer-reported Phase 3 studies (STEP and SURMOUNT programs). Individual results vary.
**$50/month pricing reflects the federal Medicare GLP-1 Bridge Program launching July 1, 2026 for qualifying beneficiaries. Eligibility is determined clinically.
What actually matters in the decision.
Mechanism of action
Wegovy is a single-pathway GLP-1 agonist. Zepbound activates both GLP-1 and GIP receptors — the dual mechanism is part of why trial weight loss is higher on average. Whether that extra mechanism is right for you depends on your full metabolic picture.
Side-effect tolerance
Both medications commonly cause nausea, constipation, and reduced appetite early in dosing. Some patients tolerate one significantly better than the other. The right choice is often the one your body adjusts to without disrupting nutrition and hydration.
Existing conditions and medications
Personal and family history of medullary thyroid cancer, pancreatitis, severe gastrointestinal conditions, and certain medications impact if GLP-1 medications are appropriate. This is the part that will be discussed between the patient and their provider.
Muscle preservation and healthy aging
For Medicare-age patients especially, the goal isn't maximum weight loss — it's metabolic health that protects muscle mass, mobility, and independence. The medication is one tool inside a broader plan.
A note before you decide.
This page is educational, not medical advice. The right medication — or whether a GLP-1 is right for you at all — is a clinical decision that depends on your full health history.
- Both medications are FDA-approved for chronic weight management in adults meeting specific BMI criteria.
- Neither is a substitute for nutrition, sleep, strength training, or addressing underlying metabolic drivers.
- Both require ongoing clinical oversight — including monitoring for muscle loss, nutritional gaps, and side effects.